Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Sanctuary Advisors LLC

Sanctuary Advisors LLC lowered its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 21.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 79,113 shares of the company’s stock after selling 21,545 shares during the period. Sanctuary Advisors LLC owned approximately 0.13% of Galectin Therapeutics worth $220,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GALT. Commonwealth Equity Services LLC boosted its position in shares of Galectin Therapeutics by 317.6% during the second quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock worth $1,092,000 after buying an additional 367,610 shares during the period. Soltis Investment Advisors LLC purchased a new position in Galectin Therapeutics during the 3rd quarter valued at about $387,000. Bank of New York Mellon Corp acquired a new position in Galectin Therapeutics in the 2nd quarter valued at about $146,000. Kovitz Investment Group Partners LLC purchased a new stake in Galectin Therapeutics during the third quarter worth about $117,000. Finally, Squarepoint Ops LLC increased its stake in Galectin Therapeutics by 75.4% during the second quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock worth $190,000 after purchasing an additional 36,139 shares during the period. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Price Performance

GALT stock opened at $1.15 on Monday. The business’s 50-day moving average is $2.34 and its two-hundred day moving average is $2.43. The firm has a market capitalization of $72.18 million, a P/E ratio of -1.58 and a beta of 0.69. Galectin Therapeutics Inc. has a 1 year low of $0.73 and a 1 year high of $4.27.

Insider Buying and Selling

In other news, CFO Jack W. Callicutt sold 40,000 shares of Galectin Therapeutics stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.89, for a total transaction of $35,600.00. Following the completion of the sale, the chief financial officer now directly owns 7,614 shares of the company’s stock, valued at approximately $6,776.46. The trade was a 84.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joel Lewis sold 56,000 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.89, for a total value of $49,840.00. Following the completion of the transaction, the chief executive officer now directly owns 897,012 shares in the company, valued at $798,340.68. This trade represents a 5.88 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 15,500 shares of company stock worth $23,000 and have sold 109,654 shares worth $97,456. Insiders own 50.10% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on GALT. HC Wainwright restated a “neutral” rating on shares of Galectin Therapeutics in a report on Friday. StockNews.com upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th.

Galectin Therapeutics Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.